Illumina (NASDAQ:ILMN) Downgraded by Wall Street Zen to “Hold”

Wall Street Zen cut shares of Illumina (NASDAQ:ILMN) from a buy rating to a hold rating in a research report sent to investors on Saturday morning.

Several other equities analysts have also issued reports on the company. Evercore restated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Royal Bank Of Canada started coverage on Illumina in a research report on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price objective for the company. Sanford C. Bernstein started coverage on Illumina in a report on Friday, June 26th. They set a “market perform” rating and a $185.00 price objective on the stock. Guggenheim boosted their price objective on Illumina from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, JPMorgan Chase & Co. upgraded Illumina from a “neutral” rating to an “overweight” rating and upped their target price for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Nine research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $156.88.

Illumina Price Performance

Shares of Illumina stock opened at $186.65 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. The company has a market cap of $28.24 billion, a PE ratio of 33.94, a price-to-earnings-growth ratio of 3.49 and a beta of 1.47. The firm has a fifty day moving average price of $166.44 and a two-hundred day moving average price of $143.34. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $196.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Analysts expect that Illumina will post 5.22 EPS for the current year.

Insider Activity

In other Illumina news, insider Scott M. Davies sold 615 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares in the company, valued at $3,771,540. This trade represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the sale, the senior vice president owned 15,056 shares in the company, valued at approximately $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,003,769 shares of company stock valued at $155,710,908. 2.90% of the stock is owned by company insiders.

Institutional Trading of Illumina

Large investors have recently bought and sold shares of the stock. Insight Wealth Strategies LLC bought a new stake in Illumina in the second quarter valued at $6,062,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Illumina during the second quarter valued at $223,000. FNY Investment Advisers LLC boosted its stake in shares of Illumina by 30.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 650 shares of the life sciences company’s stock valued at $114,000 after purchasing an additional 150 shares in the last quarter. Elevation Wealth Partners LLC boosted its stake in shares of Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after purchasing an additional 84 shares in the last quarter. Finally, PensionDanmark Pensionsforsikringsaktieselskab boosted its stake in shares of Illumina by 9.0% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 37,664 shares of the life sciences company’s stock valued at $6,622,000 after purchasing an additional 3,100 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.